<SEC-DOCUMENT>0001206774-14-001934.txt : 20140624
<SEC-HEADER>0001206774-14-001934.hdr.sgml : 20140624
<ACCEPTANCE-DATETIME>20140612060051
ACCESSION NUMBER:		0001206774-14-001934
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20140611
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140612
DATE AS OF CHANGE:		20140612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		14905950

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geron_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=center><B><FONT face="Times New Roman" size=2>UNITED STATES <BR></FONT></B><B><FONT face="Times New Roman" size=2>SECURITIES AND EXCHANGE COMMISSION<BR>WASHINGTON, D.C. 20549
<BR>___________<BR></FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>FORM 8-K </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>CURRENT REPORT<BR></FONT></B><B><FONT face="Times New Roman" size=2>PURSUANT TO SECTION 13 OR 15(d) OF THE <BR>SECURITIES EXCHANGE
ACT OF 1934</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>Date of Report (Date of earliest event
reported): </FONT><B><FONT face="Times New Roman" size=2>June 11, 2014</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON CORPORATION</FONT></B><FONT face="Times New Roman" size=2> <BR></FONT><FONT face="Times New Roman" size=2>(Exact name of registrant
as specified in its charter) </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>Delaware</FONT></B></TD>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>0-20859</FONT></B></TD>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>75-2287752</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(State or other
jurisdiction</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(Commission File Number)</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(IRS Employer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>of incorporation)</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>Identification
  No.)</FONT></TD></TR></TABLE><BR>
<P align=center><B><FONT face="Times New Roman" size=2>149 COMMONWEALTH DRIVE, SUITE
2070<BR>MENLO PARK, CALIFORNIA 94025 <BR></FONT></B><FONT face="Times New Roman" size=2>(Address of principal executive offices, including zip code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>(650) 473-7700<BR></FONT></B><FONT face="Times New Roman" size=2>(Registrant&#146;s telephone number, including area code)
</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>N/A<BR></FONT></B><FONT face="Times New Roman" size=2>(Former name or former address, if changed since last report) </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </FONT></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face=Wingdings size=2>o&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Written communications pursuant
      to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD width="100%"><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face=Wingdings size=2>o&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Soliciting material pursuant to
      Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD width="100%"><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face=Wingdings size=2>o&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Pre-commencement communications
      pursuant to Rule 14d-2(b) under the Exchange Act (17 </FONT><FONT face="Times New Roman" size=2>CFR 240.14d-2(b))</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD width="100%"><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face=Wingdings size=2>o&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Pre-commencement communications
      pursuant to Rule 13e-4(c) under the Exchange Act (17 </FONT><FONT face="Times New Roman" size=2>CFR 240.13e-4(c))</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><FONT face="Times New Roman" size=2>Item 8.01. Other Events.
</FONT></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>On June 12, 2014, Geron Corporation issued
a press release entitled &#147;Geron Reports Removal of Partial Clinical Hold on
Myelofibrosis IST.&#148; A copy of the press release is attached as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated herein by
reference.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Item 9.01. Financial Statements and
Exhibits.</FONT></B></P>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(d)</FONT></TD>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%" colSpan=3><FONT face="Times New Roman" size=2>Exhibits.</FONT></TD></TR>
  <TR>
    <TD noWrap></TD>
    <TD width="100%" colSpan=5>&nbsp;</TD></TR>
  <TR>
    <TD noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap><B><FONT face="Times New Roman" size=2>Exhibit No.</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" width="100%"><STRONG><FONT size=2 face="Times New Roman">Description</FONT></STRONG></TD></TR>
  <TR>
    <TD noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD noWrap><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center; background-color: Silver"><FONT size=2 face="Times New Roman">99.1</FONT></TD>
    <TD NOWRAP STYLE="background-color: Silver"><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD>
    <TD STYLE="width: 100%; background-color: Silver"><FONT size=2 face="Times New Roman">Press release, dated June 12,
      2014, entitled &#147;Geron Reports Removal of Partial Clinical Hold on
      Myelofibrosis IST.&#148;</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>1</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>SIGNATURE </FONT></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized. </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="49%" colSpan=2><FONT face="Times New Roman" size=2>GERON CORPORATION</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=3>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Date: June 12, 2014</FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=2 face="Times New Roman">By:&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="48%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;/s/ Stephen N. Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="48%"><FONT face="Times New Roman" size=2>Stephen N. Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="48%"><FONT face="Times New Roman" size=2>Executive Vice President,
  General</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="48%"><FONT face="Times New Roman" size=2>Counsel and Corporate
  Secretary</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>2</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><U><FONT face="Times New Roman" size=2>EXHIBIT</FONT></U></B><B><U><FONT face="Times New Roman" size=2> </FONT></U></B><B><U><FONT face="Times New Roman" size=2>INDEX</FONT></U></B><B><FONT face="Times New Roman" size=2> </FONT></B></P>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=2>Exhibit No.</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><STRONG><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="95%"><B><FONT face="Times New Roman" size=2>Description</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: center; width: 3%; background-color: Silver"><FONT face="Times New Roman" size=2>99.1</FONT></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; background-color: Silver"><STRONG><FONT size=2 face="Times New Roman">&nbsp;</FONT></STRONG></TD>
    <TD STYLE="text-align: left; width: 95%; background-color: Silver"><FONT face="Times New Roman" size=2>Press release, dated June 12, 2014, entitled
      &#147;Geron Reports Removal of Partial Clinical Hold on Myelofibrosis
      IST.&#148;</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>PRESS RELEASE, DATED JUNE 12, 2014
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=right><B><FONT face="Times New Roman" size=2>EXHIBIT 99.1 </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>PRESS RELEASE, DATED JUNE 12, 2014
</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>Geron Reports Removal of Partial
Clinical Hold on Myelofibrosis IST </FONT></B></P>
<P align=left><B><FONT face="Times New Roman" size=2>Menlo Park, Calif., June 12,
2014</FONT></B><FONT face="Times New Roman" size=2> &#150; Geron Corporation (Nasdaq: GERN)
announced today that the U.S. Food and Drug Administration (FDA) has removed the
partial clinical hold on the investigator-sponsored clinical trial of imetelstat
in myelofibrosis (Myelofibrosis IST). The partial clinical hold was placed in
March 2014 due to a safety signal of hepatotoxicity that was identified in
clinical trials of imetelstat. In order to resolve the partial clinical hold,
the investigator, Dr. Ayalew Tefferi of Mayo Clinic, Rochester, Minnesota, was
required to provide follow-up information regarding reversibility of
hepatotoxicity for all patients who received imetelstat in the Myelofibrosis
IST. In its letter dated June 11, 2014, the FDA informed the investigator that
it had completed the review of his complete response submission and concluded
that the Myelofibrosis IST may proceed. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>As previously announced, the Myelofibrosis
IST ceased enrolling new patients in January 2014, and Mayo Clinic did not cite
any safety concerns as the basis for that decision. Previously enrolled patients
who are deriving clinical benefit continue to receive treatment with imetelstat.
</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Geron&#146;s Investigational New Drug (IND)
application for imetelstat remains on full clinical hold affecting the company&#146;s
clinical trials in essential thrombocythemia or polycythemia vera and in
multiple myeloma. Until the FDA lifts the full clinical hold on Geron&#146;s IND, the
company is unable to submit any new clinical trial protocols to the FDA under
the company&#146;s IND for imetelstat and is unable to initiate any new clinical
trials for imetelstat in the United States. The company is working diligently to
seek release of the full clinical hold. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>About Geron </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Geron is a clinical stage
biopharmaceutical company developing a first-in-class telomerase inhibitor,
imetelstat, in hematologic myeloid malignancies. For more information about
Geron, visit www.geron.com.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>CONTACT: <BR></FONT><FONT face="Times New Roman" size=2>Anna Krassowska, Ph.D.<BR>Investor and Media Relations <BR></FONT><FONT face="Times New Roman" size=2>650-473-7765<BR>investor@geron.com<BR>media@geron.com
</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>### </FONT></P>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
